Cordis Makes First Big Post-Cardinal Deal: Agrees To Pay $1.1BN For MedAlliance
Executive Summary
Cordis plans to acquire MedAlliance, the developer of the Selution SLR drug-eluting vascular balloon, for up to $1.135bn. As part of the deal, Cordis will immediately begin to co-promote Selution SLR in every market where it is available.
You may also be interested in...
Minute Insight: Cordis-MedAlliance Deal Formalized, Less Than One Year After Announcement
The $1.1bn acquisition of drug-eluting balloon developer MedAlliance will help Cordis return to its roots as an innovative leader in interventional cardiology.
J&J Pumps MedTech Growth; Offers $16.6BN+ For Abiomed
Johnson & Johnson plans to buy Abiomed for $380 per share – about $16.6bn in total – plus up to $35 per share in potential commercial and clinical milestone-contingent payments. Abiomed is the clear leader in percutaneous circulatory support technology, but would benefit from J&J's reach and resources while complementing J&J's Biosense Webster electrophysiology business.
Cardio Catch-Up: Gel For Fixing Heart Attacks, ‘Uncaged’ Coronary Stents, And More
Medtech Insight’s Cardiovascular Catch-Up highlights recent news on cardiovascular tech innovations in the last two months. Part II of this month’s update includes innovative research and development news from smaller companies and research labs that you may have missed.